25 April 2023 – Congratulations to Neurelis on their accepted presentations at the upcoming Annual Meeting of the American Academy of Neurolgy. PLC has supported the clinical development and regulatory pathway of VALTOCO® from inception through NDA approval and continues to provide clinical oversight of ongoing trials and regulatory support for Neurelis and their continuing drug product development in the US.
NEURELIS ANNOUNCES FOUR POSTER PRESENTATIONS AT THE 75TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY
- Quality of life and overall duration of seizures data with use of VALTOCO® (diazepam nasal spray) CIV to be presented at AAN
